Xeljanz

FDA approves Pfizer's rheumatoid arthritis treatment

FDA approves Pfizer's rheumatoid arthritis treatment

Federal regulators recently approved Pfizer's new Xeljanz treatment for rheumatoid arthritis. Xeljanz was approved for patients with moderate to severe rheumatoid arthritis who did not benefit from the oral treatment methotrexate.

Pfizer gets FDA approval for rheumatoid arthritis treatment

By

Federal regulators approved Pfizer's new Xeljanz treatment for rheumatoid arthritis Tuesday. The potentially lucrative drug is now poised to enter a market that already features Humira, Abbott Laboratories' top-selling rheumatoid arthritis treatment.